Go Pro
→ Has Dylan Jovine lost his mind? (From Behind the Markets) (Ad)tc pixel Free HOWL Stock Alerts

Werewolf Therapeutics (HOWL) Competitors

Werewolf Therapeutics logo
$0.99 +0.01 (+0.75%)
Closing price 09/23/2026 04:00 PM Eastern
Extended Trading
$1.00 +0.01 (+0.57%)
As of 04:41 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

HOWL vs. VYGR, ORGO, NBP, DTIL, and MDWD

Should you buy Werewolf Therapeutics stock or one of its competitors? Werewolf Therapeutics's main competitors and comparable companies include Voyager Therapeutics (VYGR), Organogenesis (ORGO), I-Mab (NBP), Precision BioSciences (DTIL), and MediWound (MDWD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Werewolf Therapeutics compare to Voyager Therapeutics?

Voyager Therapeutics (NASDAQ:VYGR) and Werewolf Therapeutics (NASDAQ:HOWL) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

Werewolf Therapeutics has lower revenue, but higher earnings than Voyager Therapeutics. Voyager Therapeutics is trading at a lower price-to-earnings ratio than Werewolf Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Voyager Therapeutics$40.37M4.38-$119.72M-$1.80N/A
Werewolf Therapeutics$1.88M25.58-$60.82M-$0.76N/A

Voyager Therapeutics has a beta of 1.32, indicating that its stock price is 32% more volatile than the broader market. Comparatively, Werewolf Therapeutics has a beta of 0.51, indicating that its stock price is 49% less volatile than the broader market.

48.0% of Voyager Therapeutics shares are held by institutional investors. Comparatively, 64.8% of Werewolf Therapeutics shares are held by institutional investors. 12.7% of Voyager Therapeutics shares are held by insiders. Comparatively, 23.6% of Werewolf Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Voyager Therapeutics presently has a consensus target price of $16.50, indicating a potential upside of 474.91%. Werewolf Therapeutics has a consensus target price of $4.00, indicating a potential upside of 304.29%. Given Voyager Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Voyager Therapeutics is more favorable than Werewolf Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Voyager Therapeutics
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.75
Werewolf Therapeutics
1 Sell rating(s)
4 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.14

In the previous week, Voyager Therapeutics had 1 more articles in the media than Werewolf Therapeutics. MarketBeat recorded 1 mentions for Voyager Therapeutics and 0 mentions for Werewolf Therapeutics. Voyager Therapeutics' average media sentiment score of 0.00 equaled Werewolf Therapeutics'average media sentiment score.

Company Overall Sentiment
Voyager Therapeutics Neutral
Werewolf Therapeutics Neutral

Werewolf Therapeutics has a net margin of 0.00% compared to Voyager Therapeutics' net margin of -312.63%. Voyager Therapeutics' return on equity of -57.92% beat Werewolf Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Voyager Therapeutics-312.63% -57.92% -45.00%
Werewolf Therapeutics N/A -166.99%-59.88%

Summary

Voyager Therapeutics beats Werewolf Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Werewolf Therapeutics compare to Organogenesis?

Werewolf Therapeutics (NASDAQ:HOWL) and Organogenesis (NASDAQ:ORGO) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, earnings, dividends, analyst recommendations, institutional ownership and valuation.

Werewolf Therapeutics has a beta of 0.51, meaning that its share price is 49% less volatile than the broader market. Comparatively, Organogenesis has a beta of 1.29, meaning that its share price is 29% more volatile than the broader market.

In the previous week, Organogenesis had 3 more articles in the media than Werewolf Therapeutics. MarketBeat recorded 3 mentions for Organogenesis and 0 mentions for Werewolf Therapeutics. Organogenesis' average media sentiment score of 0.54 beat Werewolf Therapeutics' score of 0.00 indicating that Organogenesis is being referred to more favorably in the news media.

Company Overall Sentiment
Werewolf Therapeutics Neutral
Organogenesis Positive

64.8% of Werewolf Therapeutics shares are held by institutional investors. Comparatively, 49.6% of Organogenesis shares are held by institutional investors. 23.6% of Werewolf Therapeutics shares are held by insiders. Comparatively, 18.8% of Organogenesis shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Werewolf Therapeutics currently has a consensus target price of $4.00, indicating a potential upside of 304.29%. Organogenesis has a consensus target price of $4.33, indicating a potential upside of 198.85%. Given Werewolf Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Werewolf Therapeutics is more favorable than Organogenesis.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Werewolf Therapeutics
1 Sell rating(s)
4 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.14
Organogenesis
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67

Werewolf Therapeutics has a net margin of 0.00% compared to Organogenesis' net margin of -19.94%. Organogenesis' return on equity of -23.89% beat Werewolf Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Werewolf TherapeuticsN/A -166.99% -59.88%
Organogenesis -19.94%-23.89%-11.13%

Organogenesis has higher revenue and earnings than Werewolf Therapeutics. Organogenesis is trading at a lower price-to-earnings ratio than Werewolf Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Werewolf Therapeutics$1.88M25.58-$60.82M-$0.76N/A
Organogenesis$564.17M0.33$37.03M-$0.86N/A

Summary

Werewolf Therapeutics beats Organogenesis on 9 of the 16 factors compared between the two stocks.

How does Werewolf Therapeutics compare to I-Mab?

Werewolf Therapeutics (NASDAQ:HOWL) and I-Mab (NASDAQ:NBP) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, analyst recommendations, earnings, risk, valuation, profitability and institutional ownership.

Werewolf Therapeutics currently has a consensus target price of $4.00, indicating a potential upside of 304.29%. I-Mab has a consensus target price of $9.00, indicating a potential upside of 488.24%. Given I-Mab's higher possible upside, analysts plainly believe I-Mab is more favorable than Werewolf Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Werewolf Therapeutics
1 Sell rating(s)
4 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.14
I-Mab
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

I-Mab's return on equity of 0.00% beat Werewolf Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Werewolf TherapeuticsN/A -166.99% -59.88%
I-Mab N/A N/A N/A

64.8% of Werewolf Therapeutics shares are owned by institutional investors. Comparatively, 38.4% of I-Mab shares are owned by institutional investors. 23.6% of Werewolf Therapeutics shares are owned by insiders. Comparatively, 22.1% of I-Mab shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Werewolf Therapeutics has a beta of 0.51, indicating that its share price is 49% less volatile than the broader market. Comparatively, I-Mab has a beta of 1.5, indicating that its share price is 50% more volatile than the broader market.

I-Mab has higher revenue and earnings than Werewolf Therapeutics. I-Mab is trading at a lower price-to-earnings ratio than Werewolf Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Werewolf Therapeutics$1.88M25.58-$60.82M-$0.76N/A
I-Mab$3.89M45.49-$46.27M-$0.36N/A

In the previous week, I-Mab had 1 more articles in the media than Werewolf Therapeutics. MarketBeat recorded 1 mentions for I-Mab and 0 mentions for Werewolf Therapeutics. Werewolf Therapeutics' average media sentiment score of 0.00 beat I-Mab's score of -1.00 indicating that Werewolf Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Werewolf Therapeutics Neutral
I-Mab Negative

Summary

I-Mab beats Werewolf Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Werewolf Therapeutics compare to Precision BioSciences?

Werewolf Therapeutics (NASDAQ:HOWL) and Precision BioSciences (NASDAQ:DTIL) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership and valuation.

Werewolf Therapeutics has a net margin of 0.00% compared to Precision BioSciences' net margin of -96.73%. Precision BioSciences' return on equity of -72.52% beat Werewolf Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Werewolf TherapeuticsN/A -166.99% -59.88%
Precision BioSciences -96.73%-72.52%-32.25%

Werewolf Therapeutics presently has a consensus price target of $4.00, indicating a potential upside of 304.29%. Precision BioSciences has a consensus price target of $32.25, indicating a potential upside of 407.08%. Given Precision BioSciences' stronger consensus rating and higher possible upside, analysts clearly believe Precision BioSciences is more favorable than Werewolf Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Werewolf Therapeutics
1 Sell rating(s)
4 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.14
Precision BioSciences
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.60

64.8% of Werewolf Therapeutics shares are owned by institutional investors. Comparatively, 38.0% of Precision BioSciences shares are owned by institutional investors. 23.6% of Werewolf Therapeutics shares are owned by insiders. Comparatively, 2.7% of Precision BioSciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Precision BioSciences has higher revenue and earnings than Werewolf Therapeutics. Precision BioSciences is trading at a lower price-to-earnings ratio than Werewolf Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Werewolf Therapeutics$1.88M25.58-$60.82M-$0.76N/A
Precision BioSciences$45.06M3.90-$45.72M-$2.80N/A

In the previous week, Precision BioSciences had 2 more articles in the media than Werewolf Therapeutics. MarketBeat recorded 2 mentions for Precision BioSciences and 0 mentions for Werewolf Therapeutics. Precision BioSciences' average media sentiment score of 0.20 beat Werewolf Therapeutics' score of 0.00 indicating that Precision BioSciences is being referred to more favorably in the news media.

Company Overall Sentiment
Werewolf Therapeutics Neutral
Precision BioSciences Neutral

Werewolf Therapeutics has a beta of 0.51, indicating that its share price is 49% less volatile than the broader market. Comparatively, Precision BioSciences has a beta of 1.24, indicating that its share price is 24% more volatile than the broader market.

Summary

Precision BioSciences beats Werewolf Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Werewolf Therapeutics compare to MediWound?

Werewolf Therapeutics (NASDAQ:HOWL) and MediWound (NASDAQ:MDWD) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, analyst recommendations, media sentiment, risk, institutional ownership and dividends.

Werewolf Therapeutics has a beta of 0.51, indicating that its share price is 49% less volatile than the broader market. Comparatively, MediWound has a beta of 0.14, indicating that its share price is 86% less volatile than the broader market.

Werewolf Therapeutics has a net margin of 0.00% compared to MediWound's net margin of -170.10%. MediWound's return on equity of -47.24% beat Werewolf Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Werewolf TherapeuticsN/A -166.99% -59.88%
MediWound -170.10%-47.24%-24.27%

MediWound has higher revenue and earnings than Werewolf Therapeutics. MediWound is trading at a lower price-to-earnings ratio than Werewolf Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Werewolf Therapeutics$1.88M25.58-$60.82M-$0.76N/A
MediWound$16.96M10.34-$23.88M-$1.80N/A

In the previous week, MediWound had 5 more articles in the media than Werewolf Therapeutics. MarketBeat recorded 5 mentions for MediWound and 0 mentions for Werewolf Therapeutics. MediWound's average media sentiment score of 0.33 beat Werewolf Therapeutics' score of 0.00 indicating that MediWound is being referred to more favorably in the news media.

Company Overall Sentiment
Werewolf Therapeutics Neutral
MediWound Neutral

64.8% of Werewolf Therapeutics shares are held by institutional investors. Comparatively, 46.8% of MediWound shares are held by institutional investors. 23.6% of Werewolf Therapeutics shares are held by company insiders. Comparatively, 9.2% of MediWound shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Werewolf Therapeutics currently has a consensus target price of $4.00, indicating a potential upside of 304.29%. MediWound has a consensus target price of $33.00, indicating a potential upside of 141.76%. Given Werewolf Therapeutics' higher probable upside, equities research analysts plainly believe Werewolf Therapeutics is more favorable than MediWound.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Werewolf Therapeutics
1 Sell rating(s)
4 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.14
MediWound
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40

Summary

Werewolf Therapeutics and MediWound tied by winning 8 of the 16 factors compared between the two stocks.

Get Werewolf Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for HOWL and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HOWL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

HOWL vs. The Competition

Export
MetricWerewolf TherapeuticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$47.72M$3.98B$7.31B$13.29B
Dividend YieldN/A3.63%2.52%12.57%
P/E Ratio-1.3013.88274.0925.69
Price / Sales25.581,353.16642.5579.71
Price / CashN/A113.2977.8052.76
Price / Book1.9415.4010.476.32
Net Income-$60.82M-$22.82M$3.49B$359.73M
7 Day Performance2.74%-1.74%-0.68%0.17%
1 Month Performance12.01%-6.20%-3.18%-3.27%
1 Year Performance-52.32%30.64%15.12%5.58%

Werewolf Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HOWL
Werewolf Therapeutics
2.0898 of 5 stars		$0.99
+0.8%		$4.00
+304.3%		-44.7%$47.72M$1.88MN/A14
VYGR
Voyager Therapeutics
2.6255 of 5 stars		$3.09
-3.1%		$16.50
+434.0%		-30.0%$190.41M$40.37MN/A141
ORGO
Organogenesis
1.7612 of 5 stars		$1.46
-2.7%		$4.33
+196.8%		-69.5%$187.87M$564.17MN/A854
NBP
I-Mab
2.2951 of 5 stars		$1.59
-1.2%		$9.00
+466.0%		N/A$183.88MN/AN/A30
DTIL
Precision BioSciences
2.1819 of 5 stars		$6.61
-3.6%		$32.25
+387.9%		+30.3%$182.45M$45.06MN/A67

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:HOWL) was last updated on 9/24/2026 by MarketBeat.com Staff.
From Our Partners
How to get a stake in Anthropic — before the IPO
Anthropic, the maker of Claude AI, has reportedly filed for an IPO that could arrive as early as October. Its ...
Weiss Ratings | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Why I believe the AI market will split in Q4
Matt McCall, who recommended Nvidia near $6 a share, says the AI market is splitting in two - just like the do...
The Oxford Club | Sponsoredtc pixel
My next big call (under $1)
While the Senate was failing to pass the CLARITY Act, the SEC already had its own crypto framework on the tabl...
Crypto 101 Media | Sponsoredtc pixel
Shocking new footage just released
Gerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...
Digest Publishing | Sponsoredtc pixel
Major Buy Alert Issued for September 30th
Keith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...
TradeSmith | Sponsoredtc pixel
If you keep cash in a U.S. bank account… read this NOW
Since 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...
Banyan Hill Publishing | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel